Smith & Nephew (SNN) Stock: Buy, Sell, or Hold?
SNN - Smith & Nephew plc
$26.42
-0.16 (-0.60%)
▼
5d:
-1.82%
30d:
-7.82%
90d:
-13.52%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When SNN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SNN shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SNN shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$49.14
Based on 6.2% avg growth
INTRINSIC VALUE TODAY
$30.51
13.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNN is currently trading at $26.42, which is considered oversold relative to its 30-day fair value range of $27.02 to $28.85. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.0) compared to its historical average (15.1). Remarkably, the market is currently pricing in an annual earnings decline of 10.1% over the next few years. This pessimistic expectation contrasts with the company's recent 5.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, SNN is in a downtrend. The price is currently testing key support at $26.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNN scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $32.72 (+23.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNN is in a downtrend. The price is currently testing key support at $26.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNN scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $32.72 (+23.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$27.02 -
$28.85
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (28/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.9% below Wall St target ($32.72)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$27.02 -
$28.85
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$26.12
Resistance Level
$27.83
Current Trend
Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.96
Wall Street Target
$32.72
(+23.9%)
Revenue Growth (YoY)
4.6%
Earnings Growth (YoY)
5.7%
Profit Margin
10.1%
Valuation Discount vs History
-10.1% cheaper
PE vs Historical
11.0 vs 15.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-10.1%
(market-implied from PE analysis)
1-Year Target
$23.78
(-10%)
2-Year Target
$21.40
(-19%)
3-Year Target
$19.26
(-27%)
3-Yr Target (if PE normalizes)
(PE: 11→15)
$26.53
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 8.4%)
$62.61
(+137%)
Base:
(SPY PE: 11.0, Growth: 8.4%)
$33.64
(+27%)
Bear:
(PE: 9.3, Growth: 8.4%)
$28.59
(+8%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 18.33 | Current EPS (TTM): $1.45
Bull Case
$48.60
(+84%)
Analyst growth 66.2%, PE expands to 20.2
Base Case
$44.19
(+67%)
Market implied 66.2%, PE stable at 18.3
Bear Case
$18.07
(-32%)
Severe decline -20.0%, PE contracts to 15.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.0 to 15.1
Stabilization Target:
$36.40
(+37.8%)
PE Expansion Potential:
+37.8%
Share & Embed Analysis
Last updated: October 03, 2026 11:15 AM ET
Data refreshes hourly during market hours. Next update: 12:15 PM
Data refreshes hourly during market hours. Next update: 12:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$61 | 62 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$369 | 69 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 47 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 64 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 58 HOLD |
